Clinical Trials Logo
NCT number NCT03419455
Study type Observational
Source Harvard Medical School
Contact
Status Active, not recruiting
Phase N/A
Start date January 2017
Completion date June 2021

Clinical Trial Summary

Obesity is associated with increased risk of several cancers. Suggested mechanisms mediating the obesity-cancer associations include hyperinsulinemia and altered IGF signaling, changes in sex hormone levels as well as altered secretion of adipokines and inflammatory proteins. However, little is known about the influence of lifetime adiposity on the relevant biomarkers. Moreover, although diet has been suggested to ameliorate the adverse metabolic effects of obesity, convincing evidence regarding how dietary factors may influence obesity-related carcinogenic pathways remains lacking. Thus, in the current project, the investigators aim to 1) examine the associations between trajectories of body fatness and plasma biomarker levels of the insulin/IGF system, sex hormones and biomarkers of inflammatory response including adipokines; 2) investigate how nutritional factors may modulate these obesity-related biomarkers. The investigators propose to utilize two large ongoing cohorts of US men and women, the Nurses' Health Study and Health Professionals Follow-up Study.


Clinical Trial Description

According to the International Agency for Research on Cancer (IARC), there is sufficient evidence that avoidance of weight gain reduces the risk of several cancers, including colorectal, breast (postmenopause), pancreatic, endometrial, kidney (renal-cell), liver, gallbladder, oesophageal (adenocarcinoma), multiple myeloma, meningioma, ovarian, thyroid and stomach (cardia) cancer. Several mechanisms have been suggested to mediate the obesity-cancer association, including increased insulin levels and bioavailability of insulin-like growth factor (IGF)-1, low-grade chronic inflammation, and changes in sex hormone levels.

In previous studies, the investigators have identified five heterogeneous trajectory groups of body fatness from age five and up to 60 years (lean-stable, lean-moderate increase, lean-marked increase, medium-stable, and heavy-stable/increase). These trajectories have been associated with distinct patterns of cancer incidence and mortality. Having excess body weight at any life period have been associated with increased risk of total and obesity related cancers. How the various trajectories of body shape relate to cancer relevant risk biomarkers is however yet to be determined.

To gain a better understanding of the complex interplay between obesity, obesity-related risk biomarkers and cancer development, the investigators aim to examine the associations between trajectories of body fatness and cancer relevant risk biomarkers in the Nurses' Health Study and Health Professionals Follow-up Study. Moreover, the investigators will examine how nutritional factors, such coffee intake, may modulate the levels of these biomarkers.

The investigators hypothesize that in general individuals who have excess body weight at any life period will have a more unfavorable biomarker profile than those who are lean across the lifespan, although a different pattern may be expected for some markers. Also, the investigators hypothesize that some nutritional factors, such high intake of coffee, may ameliorate the adverse metabolic effects of obesity by modulating the levels of these biomarkers.


Study Design


Related Conditions & MeSH terms


See also
  Status Clinical Trial Phase
Recruiting NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Recruiting NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT03299881 - Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss N/A
Enrolling by invitation NCT03063606 - Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment Phase 2/Phase 3
Completed NCT03317587 - Inspiring Nutritious Selections and Positive Intentions Regarding Eating and Exercise (INSPIRE) N/A
Completed NCT02235961 - Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects Phase 1
Completed NCT03195712 - Metabolically Healthy Obesity: Correlations Between BMI and Metabolic Syndrome Biomarkers N/A
Recruiting NCT00341406 - Fat Cell Size in Insulin Resistance N/A
Recruiting NCT03241121 - Study of Eating Patterns With a Smartphone App and the Effects of Time Restricted Feeding in the Metabolic Syndrome N/A
Recruiting NCT02918279 - Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity Phase 3
Completed NCT00494767 - Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs Phase 1
Recruiting NCT03338296 - Study to Evaluate the Efficacy and Safety of Belviq XR® in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years Phase 4
Recruiting NCT03277040 - Diet, Eating, and Lifestyle Improvement for Valued Employees and Their Relatives N/A
Recruiting NCT03345368 - Effect of rTMS in Combination With a Low-carb Diet in Patients With Obesity N/A
Completed NCT01222793 - Effects of Antipsychotics on Eating and Food Craving in People With Schizophrenia N/A
Recruiting NCT03334266 - Preventing Early Childhood Obesity, Part 2: Family Spirit Nurture, Prenatal - 18 Months N/A
Recruiting NCT03119610 - The Physiologic Effects of Intranasal Oxytocin on Sarcopenic Obesity Phase 1/Phase 2
Completed NCT00976105 - Effects of Repeat Dosing of GSK1521498 Phase 1
Recruiting NCT03141346 - Improving the Eating Habits of Mother and Her Infant Via Sugar Reduction N/A